Enterprise Value
5.647B
Cash
383.8M
Avg Qtr Burn
-121.5M
Short % of Float
16.55%
Insider Ownership
6.24%
Institutional Own.
95.46%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
NULIBRY (Fosdenopterin) (BBP-870/ORGN001) Details Molybdenum cofactor deficiency type A | Approved Quarterly sales | |
Acoramidis (AG10) Details Transthyretin Amyloid Cardiomyopathy | NDA Submission | |
BBP-418 Details Limb-Girdle Muscular Dystrophy | Phase 3 Data readout | |
Encaleret Details Autosomal Dominant Hypocalcemia Type 1 | Phase 3 Data readout | |
Infigratinib Details Achondroplasia | Phase 3 Initiation | |
BBP-631 Details Congenital adrenal hyperplasia | Phase 1/2 Data readout | |
BBP-398 + OPDIVO Details Solid tumor/s, Non-small cell lung carcinoma, Lung cancer | Phase 1/2 Data readout | |
BBP- 812 Details Canavan disease | Phase 1/2 Update | |
TRUSELTIQ (infigratinib) Details Cholangiocarcinoma | Failed Discontinued |